KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Weighted Average and Diluted) (2018 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$1.35 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 221.43% to -$1.35 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.5 through Dec 2025, down 49.43% year-over-year, with the annual reading at -$6.47 for FY2025, 49.08% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$1.35 in Q4 2025 for CRISPR Therapeutics AG, down from -$1.17 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $9.44 in Q2 2021 to a low of -$2.4 in Q2 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.83 across 5 years, with a median of -$1.42 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 826.15% in 2021 and later crashed 221.43% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.74 in 2021, then increased by 19.54% to -$1.4 in 2022, then soared by 180.71% to $1.13 in 2023, then plummeted by 137.17% to -$0.42 in 2024, then plummeted by 221.43% to -$1.35 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CRSP at -$1.35 in Q4 2025, -$1.17 in Q3 2025, and -$2.4 in Q2 2025.